| Literature DB >> 33584893 |
André B Cunha1, Jie Hou1, Christin Schuelke1.
Abstract
Electrical impedance spectroscopy (EIS) measurements on cells is a proven method to assess stem cell proliferation and differentiation. Cell regenerative medicine (CRM) is an emerging field where the need to develop and deploy stem cell assessment techniques is paramount as experimental treatments reach pre-clinical and clinical stages. However, EIS measurements on cells is a method requiring extensive post-processing and analysis. As a contribution to address this concern, we developed three machine learning models for three different stem cell lines able to classify the measured data as proliferation or differentiation laying the stone for future studies on using machine learning to profile EIS measurements on stem cells spectra.Entities:
Keywords: differentiation; electrical impedance spectroscopy; long term short term memory; machine learning; proliferation; recurrent neural networks; stem cells
Year: 2019 PMID: 33584893 PMCID: PMC7851974 DOI: 10.2478/joeb-2019-0018
Source DB: PubMed Journal: J Electr Bioimpedance ISSN: 1891-5469
Figure 1Relative impedance spectra for the three cell lines for proliferation (green) and differentiation (blue) on Day 20.
Figure 21w54e-Microelectrode array with 54 measurement electrodes in a single well format. Arrangement of electrodes with diameter and horizontal and vertical spacing shown in mm.
Accuracy and loss data for both training and testing (day 20) for day 20 cell models. Maximum (green) and minimum (red) values signalled for each cell model.
| 4603c27 | IMR90c01 | IMR90-4 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 20 | 1553 | 1514 | 1 | 0 | 1517 | 1519 | 1 | 0.02 | 1552 | 1510 | 0.91 | 0.35 |
| 20 | 1520 | 1564 | 0.88 | 0.56 | 1555 | 2021 | 0.78 | 0.64 | 2020 | 1516 | 0.87 | 0.50 |
| 2012 | 1564 | 0.87 | 0.77 | 2042 | 2021 | 0.74 | 0.56 | 2022 | 1516 | 0.96 | 0.45 | |
| 2041 | 1564 | 0.94 | 0.22 | 2050 | 2021 | 0.57 | 2055 | 1516 | 0.95 | 0.42 | ||
| 2044 | 1564 | 0.15 | 2053 | 2021 | 0.72 | 0.60 | 2020 | 1556 | 0.53 | |||
| 1520 | 2047 | 0.86 | 0.55 | 1555 | 2048 | 0.77 | 0.77 | 2022 | 1556 | 0.93 | 0.47 | |
| 2012 | 2047 | 0.79 | 2042 | 2048 | 0.73 | 0.73 | 2055 | 1556 | 0.91 | 0.44 | ||
| 2041 | 2047 | 0.93 | 0.16 | 2050 | 2048 | 0.81 | 0.80 | 2020 | 2010 | 0.86 | 0.52 | |
| 2044 | 2047 | 0.82 | 2053 | 2048 | 0.71 | 2022 | 2010 | 0.46 | ||||
| 2055 | 2010 | 0.96 | 0.43 | |||||||||
| 2020 | 2013 | 0.83 | 0.55 | |||||||||
| 2022 | 2013 | 0.93 | 0.48 | |||||||||
| 2055 | 2013 | 0.92 | 0.46 | |||||||||
| 2020 | 2014 | 0.84 | 0.58 | |||||||||
| 2022 | 2014 | 0.95 | 0.51 | |||||||||
| 2055 | 2014 | 0.93 | 0.48 | |||||||||
Accuracy and loss data for both training and testing (day10) for day 20 cell models. Maximum (green) and minimum (red) values signalled for each cell model.
| 4603c27 | IMR90c01 | IMR90-4 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 20 | 1553 | 1514 | 1 | 0 | 1517 | 1519 | 1 | 0.02 | 1552 | 1510 | 0.91 | 0.35 |
| 10 | 1520 | 1564 | 0.78 | 0.65 | 1555 | 2021 | 0.66 | 0.60 | 2020 | 1516 | 0.87 | 0.60 |
| 2012 | 1564 | 0.74 | 0.56 | 2042 | 2021 | 0.77 | 2022 | 1516 | 0.80 | 0.62 | ||
| 2041 | 1564 | 0.57 | 2050 | 2021 | 0.64 | 0.90 | 2055 | 1516 | 0.90 | 0.55 | ||
| 2044 | 1564 | 0.72 | 0.60 | 2053 | 2021 | 0.64 | 0.57 | 2020 | 1556 | 0.88 | 0.59 | |
| 1520 | 2047 | 0.77 | 0.70 | 1555 | 2048 | 0.63 | 2022 | 1556 | 0.81 | 0.62 | ||
| 2012 | 2047 | 0.73 | 0.62 | 2042 | 2048 | 0.79 | 2055 | 1556 | 0.92 | 0.55 | ||
| 2041 | 2047 | 0.80 | 0.62 | 2050 | 2048 | 0.65 | 0.92 | 2020 | 2010 | 0.89 | 0.59 | |
| 2044 | 2047 | 0.65 | 2053 | 2048 | 0.65 | 0.60 | 2022 | 2010 | 0.82 | 0.61 | ||
| 2055 | 2010 | 0.54 | ||||||||||
| 2020 | 2013 | 0.86 | 0.60 | |||||||||
| 2022 | 2013 | 0.62 | ||||||||||
| 2055 | 2013 | 0.89 | 0.56 | |||||||||
| 2020 | 2014 | 0.87 | 0.63 | |||||||||
| 2022 | 2014 | 0.80 | 0.65 | |||||||||
| 2055 | 2014 | 0.91 | 0.58 | |||||||||
| Component | Concentration | |
|---|---|---|
| NIM | NPM | |
| Advanced DMEM/F12 : Neurobasal™ | 1:1 | 1:1 |
| B-27™ Supplement | 2 % (v/v) | 2 % (v/v) |
| N-2 Supplement | 1 % (v/v) | 1 % (v/v) |
| GlutaMax™ | 1 % (v/v) | 1 % (v/v) |
| LIF | 10 ng/ml | 10 ng/ml |
| CHIR99021 | 4 μM | 3 μM |
| SB431542 | 3 μM | 2 μM |
| Compound E | 0.1 μM | - |
| BSA | 0.0005 % (w/v) | 0.0005 % (w/v) |
| Component | Concentration |
|---|---|
| Astrocyte proliferation medium | |
| Neurobasal™ | |
| FBS | 10 % (v/v) |
| GlutaMax™ | 1.5 % (v/v) |
| Pen/Strep | 0.2 % (v/v) |
| Gentamicin | 0.04 % (v/v) |
| Astro-NDM | |
| DMEM/F12 | |
| Apotransferrin | 0.0095 % (w/v) |
| Ascorbic acid | 300 μM |
| cAMP | 300 nM |
| Glucose monohydrate | 33.3 mM |
| GlutaMax™ | 1 % (v/v) |
| Heparin | 0.0004 % (v/v) |
| HEPES | 5 mM |
| Insulin, human | 0.0025 % (w/v) |
| NaHCO3 | 3 mM |
| Sodium selenite | 30 nM |
| Progesterone | 20 nM |
| Putrescine | 60 nM |
| Pen/Strep | 0.2 % (v/v) |
| Gentamicin | 0.04 % (v/v) |